Rosetta and Admera OncoGxSelect Diagnostics Panel

Rosetta Genomics and Admera Health have jointly launched OncoGxSelect diagnostics panel, a next-generation sequencing-based test that detects somatic mutations and provides actionable results. The new panel uses Admera Health's industry leading NGS technology and looks at 12 genes — ALK, BRAF, EGFR, ERBB2, KIT, KRAS, MAP2K1, MET, NRAS, PIK3CA, RET, and ROS1 — commonly associated with lung cancer. It is a significant upgrade from the OncoGxLung, since it increase the number of genes examined from 5 to 12, and has the capacity to be used to diagnose other tumor types, Rosetta said. The test is a result of the 2014 marketing deal between Rosetta and Admera.